7-methoxy-4-trifluoromethylcoumarin-3-acetic acid ethyl ester | 263557-74-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid ethyl ester
• 英文别名: Ethyl 2-[7-methoxy-2-oxo-4-(trifluoromethyl)chromen-3-yl]acetate
• CAS: 263557-74-0
• 化学式: C₁₅H₁₃F₃O₅
• 分子量: 330.26
• InChiKey: LZKGBNABVBBFLZ-UHFFFAOYSA-N

物化性质

• 沸点：
  384.1±42.0 °C(predicted)
• 密度：
  1.352±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• [EN] A PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE<br/>[FR] PROMÉDICAMENT DE LA 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015165833A1

  公开（公告）日：2015-11-05

  The present invention relates to the compound (2R,2'R)-bis(((((tetrahydro-2H-pyran- 4-yl)oxy)carbonyl)oxy)methyl) 1,1'-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.

  本发明涉及化合物(2R,2'R)-双((((四氢-2H-吡喃-4-基)氧基)羰基)氧基)甲基)1,1'-己二酰基双(吡咯烷-2-羧酸酯)，包括该化合物的药物组合物以及将其用于治疗血清淀粉样蛋白P成分(SAP)耗竭有益的疾病或疾病的用途，包括淀粉样变性病、阿尔茨海默病、2型糖尿病和骨关节炎。
• A PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

  公开号：US20160075694A1

  公开（公告）日：2016-03-17

  The present invention relates to the compound (2R,2′R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate) of formula (I), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.

  本发明涉及化合物(I) (2R,2′R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate)，以及包含该化合物的制药组合物，以及该化合物在治疗疾病或疾患中的应用，其中血清淀粉样蛋白P成分(SAP)的耗竭将是有益的，包括淀粉样变性、阿尔茨海默病、2型糖尿病和骨关节炎。
• PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US20160081983A1

  公开（公告）日：2016-03-24

  The present invention relates to the compound (2R,2′R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.

  本发明涉及化合物(2R,2′R)-双(((((四氢-2H-吡喃-4-基)氧基)羰基)氧基)甲基) 1,1′-己二酰基双(吡咯烷-2-羧酸酯)，包括该化合物的制药组合物以及将其用于治疗对血清淀粉样蛋白P成分(SAP)的消耗有益的疾病或疾病的用途，包括淀粉样变性、阿尔茨海默病、2型糖尿病和骨关节炎。
• D-proline derivatives as SAP depleting agent
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US10328052B2

  公开（公告）日：2019-06-25

  The present invention relates to the compound ((2R,2′R)-bis(((tetrahydro-2H-pyran-4-carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.

  本发明涉及化合物((2R,2′R)-双(((四氢-2H-吡喃-4-甲酰)氧基)甲基)1,1′-己二酰双(吡咯烷-2-甲酸)酯、由其组成的药物组合物，以及将其用于治疗血清淀粉样蛋白 P 成分（SAP）消耗有益的疾病或失调，包括淀粉样变性、阿尔茨海默病、2 型糖尿病和骨关节炎。
• Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US10597385B2

  公开（公告）日：2020-03-24

  The present invention relates to the compound (2R,2′R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.

  本发明涉及化合物(2R,2′R)-双(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl)1,1′-adipoylbis(pyrrolidine-2-carboxylate)、由其组成的药物组合物，以及将其用于治疗血清淀粉样蛋白 P 成分（SAP）消耗有益的疾病或失调，包括淀粉样变性、阿尔茨海默病、2 型糖尿病和骨关节炎。